Pharmacy Grand Rounds
To A1C and Beyond: Exploring Renal and Cardiovascular Benefits of Antidiabetic Agents 

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Within recent years, a handful of antidiabetic agents have received approval from the FDA for improvement of cardiovascular or renal outcomes in type 2 diabetes mellitus.  Notably, several GLP-1 receptor agonists and SGLT2 inhibitors have been approved by the FDA within the last year for these indications. With these most recent updates, a gap may exist in the optimal prescribing of these medications. This presentation will review the literature leading to these and other similar recommendations in order to optimize the benefit of these agents.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Describe the recent literature examining cardiovascular benefits of GLP-1 receptor agonists and SGLT2 inhibitors.
• Discuss the body of evidence for renal outcomes with GLP-1 receptor agonists and SGLT2 inhibitors.
• Recognize situations to implement and optimize these therapies in patient care plans

Session Announcement

Session Slides

FACULTY INFORMATION

Laurel N. Lake, PharmD
PGY2 Ambulatory Care Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Laurel earned a Doctor of Pharmacy degree at the University of Wyoming in Laramie, WY. From there, she completed PGY1 training at the Cheyenne VA Medical Center in Cheyenne, WY. She is currently a PGY2 Ambulatory Care Pharmacy Resident at Mayo Clinic with practice interests in chronic disease state management, polypharmacy, and geriatrics.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Laurel N. Lake, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation.

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS